SCHEMBL5458600

SCHEMBL5458600

Cc1ccc(-c2ncco2)cc1-c1ccc(NC(=O)/C=C\c2snnc2C)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IL2 P60568 4/20 0.42
MAPK14 Q16539 4/20 0.37
POLB P06746 4/20 0.36
MAPT P10636 4/20 0.36
TP53 P04637 3/20 0.36
KDR P35968 1/20 0.34
PLK4 O00444 1/20 0.34
AURKA O14965 1/20 0.34
PDPK1 O15530 1/20 0.34
ROCK2 O75116 1/20 0.34
RPS6KA5 O75582 1/20 0.34
PRKD3 O94806 1/20 0.34
MAP4K4 O95819 1/20 0.34
PAK4 O96013 1/20 0.34
CHEK2 O96017 1/20 0.34
ABL1 P00519 1/20 0.34
NTRK1 P04629 1/20 0.34
LCK P06239 1/20 0.34
FYN P06241 1/20 0.34
CDK1 P06493 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5458607 1.00 IL2 (0.42) IL2MAPK14POLBMAPTTP53
SCHEMBL8234653 1.00 IL2 (0.42) IL2MAPK14POLBMAPTTP53
SCHEMBL5030700 0.82 MMP1 (0.48) MAPTTP53SMN1; SMN2MEN1ALDH1A1
SCHEMBL5030697 0.82 MMP1 (0.48) MAPTTP53SMN1; SMN2MEN1ALDH1A1
SCHEMBL5030695 0.82 EGFR (0.51) IL2MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5028442 0.82 MMP1 (0.50) IL2POLBMAPTTP53SMN1; SMN2
SCHEMBL8227769 0.82 EGFR (0.51) IL2MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5030705 0.82 EGFR (0.51) IL2MAPTSMN1; SMN2MEN1KMT2A
SCHEMBL5028445 0.82 MMP1 (0.50) IL2POLBMAPTTP53SMN1; SMN2
SCHEMBL8235865 0.82 MMP1 (0.50) IL2POLBMAPTTP53SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254363-A1 Substituted biaryl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-01 US claimed
US-20140121217-A1 SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES SYNTA PHARMACEUTICALS CORP. (US) 2014-05-01 US disclosed
US-8623871-B2 Substituted biaryl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2014-01-07 US disclosed
US-20070254363-A1 Substituted biaryl compounds for inflammation and immune-related uses SYNTA PHARMACEUTICALS CORP. (US) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254363-A1 Substituted biaryl compounds for inflammation and immune-related uses CCR1, CCR3, CXCR2 IL2 5/4885MAPK14 3571/4885POLB 4512/4885
US-20140121217-A1 SUBSTITUTED BIARYL COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES CCR1, CCR3, CXCR2 IL2 5/4885MAPK14 3571/4885POLB 4512/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.